SAO PAULO, Jan 9 (Reuters) – Brazilian health authority Anvisa said on Saturday that the application from São Paulo-based medical center Butantan for emergency use of a COVID-19 vaccine developed by China’s Sinovac Biotech lacks some relevant information for the analysis.

Anvisa said in a statement that Butantan did not inform, for instance, the age, gender or comorbidities of participants in trials with Sinovac’s CoronaVac vaccine. The application also missed data on the vaccine’s immunogenicity on Phase III trials and some details on the number of participants, the health authority said.

Butantan delivered its application on Friday.

Brazil’s state-run Fiocruz Institute also submitted on Friday an application for emergency use of the AstraZeneca COVID-19 vaccine. Anvisa said on Saturday that all required information has been delivered.

(Reporting by Carolina Mandl; Editing by Leslie Adler)

Our Standards: The Thomson Reuters Trust Principles.


Similar articles:

  1. Pope Francis to have COVID-19 vaccine, says it is the ethical choice for all []
  2. Commentary: This 71-year-old wants you to get a COVID-19 vaccine once you can. Here’s why []
  3. Pfizer-BioNTech vaccine can be quickly modified to combat coronavirus if it mutates []
  4. Pope Francis has appointment to be vaccinated against COVID-19 ‘next week’ []
  5. Gov. Newsom won’t jump vaccine line: ‘Don’t think that will sit well’ []
  6. COVAX offers Pfizer’s vaccine to Bangladesh []
  7. Pope Francis reveals he will get COVID vaccine; says opposition to jab is ‘suicidal denial’ []

Leave a Reply

Your email address will not be published. Required fields are marked *